Cover Image
市場調查報告書

生長抑制素第二型受體:開發平台分析

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 359828
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
生長抑制素第二型受體:開發平台分析 Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Pipeline Review, H2 2017
出版日期: 2017年10月31日 內容資訊: 英文 60 Pages
簡介

本報告提供以生長抑制素第二型受體為標的的藥物適應症,開發階段,作用機制,給藥途徑及各分子類型分析,藥物的藥理作用之相關記述,並彙整迄今的研究開發趨勢,最新的新聞和發表,藥物的主要開發企業概要,休止/中止的計劃等資訊。

簡介

  • 調查範圍

生長抑制素第二型受體概要

治療藥的開發

生長抑制素第二型受體:開發中的產品 - 各開發階段

生長抑制素第二型受體:開發中的產品 - 治療範圍別

生長抑制素第二型受體:開發中的產品 - 各適應症

生長抑制素第二型受體:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

生長抑制素第二型受體:企業開發中的產品

生長抑制素第二型受體:大學/機關開發中的產品

生長抑制素第二型受體:治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

生長抑制素第二型受體的治療藥開發企業

  • Boehringer Ingelheim GmbH
  • Crinetics Pharmaceuticals, Inc.
  • Ipsen S.A.
  • OctreoPharm Sciences GmbH
  • Progenics Pharmaceuticals, Inc.
  • Sompharmaceuticals S.A.
  • Strongbridge Biopharma plc

藥物簡介

生長抑制素第二型受體:暫停中的計劃

生長抑制素第二型受體:開發中止的產品

生長抑制素第二型受體:主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1105TDB

Summary:

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Pipeline Review, H2 2017, outlays comprehensive information on the Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Somatostatin receptor type 2 is a protein that encoded by the SSTR2 gene. Somatostatin acts at many sites to inhibit the release of many hormones and other secretory proteins. SSTR2 is expressed in highest levels in cerebrum and kidney. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 2 and 4 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively. Report covers products from therapy areas Hormonal Disorders, Oncology, Metabolic Disorders, Central Nervous System, Gastrointestinal, Genetic Disorders and Ophthalmology which include indications Acromegaly, Neuroendocrine Tumors, Chronic Pain, Diabetic Retinopathy, Neuropathic Pain, Pituitary ACTH Hypersecretion (Cushing Disease), Age Related Macular Degeneration, Gastric Motility Disorder, Gastrointestinal Tumor, Hypoglycemia, Medulloblastoma, Meningioma, Neuroblastoma, Pancreatic Tumor, Pituitary Tumor and Polycystic Kidney Disease.

Furthermore, this report also reviews key players involved in Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Somatostatin Receptor Type 2 (SRIF1 or SSTR2)
  • The report reviews Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Somatostatin Receptor Type 2 (SRIF1 or SSTR2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Somatostatin Receptor Type 2 (SRIF1 or SSTR2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Overview
    • Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Companies Involved in Therapeutics Development
    • Amryt Pharma plc
    • Crinetics Pharmaceuticals Inc
    • Daewoong Pharmaceutical Co Ltd
    • Ipsen SA
    • Progenics Pharmaceuticals Inc
    • Strongbridge Biopharma plc
    • Zucara Therapeutics Inc
  • Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Drug Profiles
    • AP-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CRN-00808 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Edotreotide Labeled Yttrium 90 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lanreotide acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lanreotide SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRL-2903 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize SSTR2 and SSTR4 for Chronic Pain and Neuropathic Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize SSTR2 for Neuroendocrine Tumors - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Antagonize Somatostatin Receptor Type 2 for Neuroendocrine Tumors - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • veldoreotide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Dormant Products
  • Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Discontinued Products
  • Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Product Development Milestones
    • Featured News & Press Releases
      • Sep 21, 2017: JDRF Funds Zucara Therapeutics Approach to Preventing Hypoglycemia in People with Type 1 Diabetes
      • Sep 18, 2017: U.S. FDA Approves New Indication for Ipsen's Somatuline Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
      • Sep 04, 2017: Ipsen To Present Data on Somatuline at European Society of Medical Oncology congress
      • Jul 13, 2017: Crinetics Pharmaceuticals Awarded $2.8 Million SBIR Grant to Support Development of Acromegaly Drug Candidate CRN00808
      • Jul 03, 2017: Somatuline Autogel 120 mg receives Japanese approval for a new indication for the treatment of gastro-entero-pancreatic neuroendocrine tumors
      • Jun 01, 2017: Ipsen To Present New Data of Lanreotide at ASCO
      • Mar 09, 2017: Ipsen announces data presentation on lanreotide (Somatuline Autogel) at the European Neuroendocrine Tumor Society (ENETS) 2017 conference
      • Feb 06, 2017: Amryt Pharma Announces positive pre-clinical study results for drug compound with potential to treat acromegaly, AP102
      • Dec 02, 2016: Amryt Pharma provides update on AP-102
      • Nov 07, 2016: FDA Orphan Drug Designation Received for Drug Compound with Potential to Treat Acromegaly
      • Sep 30, 2016: Ipsen Biopharmaceuticals Announces Nine Poster Presentations at the 2016 North American Neuroendocrine Tumor Society Symposium
      • Sep 27, 2016: Ipsen Announces Data Presentations of Lanreotide (Somatuline Autogel) at the European Society for Medical Oncology (ESMO) 2016 Congress
      • Jul 27, 2016: Supplemental Application Filed for Somatuline in Japan for Additional Indication of Neuroendocrine Tumors
      • Jun 04, 2016: Endocrine Practice Publishes ELECT Phase III Trial Results in Adults with Carcinoid Syndrome
      • Jun 02, 2016: Ipsen Announces Data Presentations of Somatuline Depot (lanreotide) Injection in Gastroenteropancreatic Neuroendocrine Tumors at American Society of Clinical Oncology Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Amryt Pharma plc, H2 2017
  • Pipeline by Crinetics Pharmaceuticals Inc, H2 2017
  • Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017
  • Pipeline by Ipsen SA, H2 2017
  • Pipeline by Progenics Pharmaceuticals Inc, H2 2017
  • Pipeline by Strongbridge Biopharma plc, H2 2017
  • Pipeline by Zucara Therapeutics Inc, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top